Topoisomerases are ubiquitous enzymes involved in maintaining genomic stability of the cell by regulating the over- or underwinding of DNA strands. Besides their customary functions, topoisomerases are important cellular targets of widely used anticancer drugs. In particular, topoisomerase IIα(Top2α) has been postulated as the primary molecular target of anthracycline's anticancer activity, whereas topoisomerase II β (Top2β), the only Top2 present in heart tissue, seems to be involved into the development of anthracycline-induced cardiotoxicity. Noteworthy, cardiotoxicity is the most frequent adverse effect of both conventional and modern anticancer targeted therapy, representing the leading noncancer-related cause of morbidity and mortality in long-term survivors. The molecular mechanisms of anthracycline-induced cardiotoxicity have been investigated for decades and, despite the numerous mechanistic hypotheses put forward, its aetiology and pathogenesis still remain controversial. This review is aimed at focusing on the double edge sword of topoisomerase-anthracycline interaction, and, in particular, on the potential role of topoisomerases in anthracyclines anticancer activity as well as in the pathogenesis of anthracycline-induced cardiotoxicity.

Mordente, A., Meucci, E., Martorana, G. E., Tavian, D., Silvestrini, A., Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity, <<CURRENT MEDICINAL CHEMISTRY>>, 2017; (24): 1-24 [http://hdl.handle.net/10807/94227]

Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity

Mordente, Alvaro
Primo
;
Meucci, Elisabetta
Secondo
;
Martorana, Giuseppe Ettore;Tavian, Daniela
Penultimo
;
Silvestrini, Andrea
Ultimo
2016

Abstract

Topoisomerases are ubiquitous enzymes involved in maintaining genomic stability of the cell by regulating the over- or underwinding of DNA strands. Besides their customary functions, topoisomerases are important cellular targets of widely used anticancer drugs. In particular, topoisomerase IIα(Top2α) has been postulated as the primary molecular target of anthracycline's anticancer activity, whereas topoisomerase II β (Top2β), the only Top2 present in heart tissue, seems to be involved into the development of anthracycline-induced cardiotoxicity. Noteworthy, cardiotoxicity is the most frequent adverse effect of both conventional and modern anticancer targeted therapy, representing the leading noncancer-related cause of morbidity and mortality in long-term survivors. The molecular mechanisms of anthracycline-induced cardiotoxicity have been investigated for decades and, despite the numerous mechanistic hypotheses put forward, its aetiology and pathogenesis still remain controversial. This review is aimed at focusing on the double edge sword of topoisomerase-anthracycline interaction, and, in particular, on the potential role of topoisomerases in anthracyclines anticancer activity as well as in the pathogenesis of anthracycline-induced cardiotoxicity.
Inglese
Mordente, A., Meucci, E., Martorana, G. E., Tavian, D., Silvestrini, A., Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity, <<CURRENT MEDICINAL CHEMISTRY>>, 2017; (24): 1-24 [http://hdl.handle.net/10807/94227]
File in questo prodotto:
File Dimensione Formato  
Topoisomerase CMC 2017.pdf

non disponibili

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Non specificato
Dimensione 1.27 MB
Formato Unknown
1.27 MB Unknown   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/94227
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 28
social impact